Intensity Therapeutics, Inc. (INTS): Price-to-Projected Revenue Ratio

INTS (Intensity Tx) - company brandmark

Patent protection for intratumoral methods creates a significant barrier to entry for competitors. The forward price-to-sales valuation trend reflects the current market sentiment, where the current mark is . Market capitalization growth is fueled by survival data for breast cancer and sarcoma. The development strategy relies on the acquisition of bio-patents and synergy with pharmaceutical behemoths within the INT230-6 projects for Intensity Therapeutics (INTS).

INTS Intensity Tx: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for intensitytherapeutics.com (INTS)

- stock price and consensus target price:
Stock Quotes Intensity Therapeutics, Inc.|INTS - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value INTS|INTS - Business Value
- book value of equity indicators:
Net Assets per Single Share Intensity Therapeutics|INTS - Total Stockholders' Equity|Market Cap to Net Assets Ratio intensitytherapeutics.com|INTS - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Intensity Therapeutics|INTS - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Intensity Therapeutics, Inc.|INTS - Aggregate Debt Obligations|Debts to Book Capitalization INTS|INTS - Long-Term Debt|Company Short-Term Debt Intensity Therapeutics|Quick Ratio intensitytherapeutics.com
- business earnings and investment ratios data:
INTS - Net Profit|Expected Profit Intensity Therapeutics|INTS - Market Cap to Net Income|Projected Price to Earnings Intensity Therapeutics, Inc.|INTS - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple INTS|INTS - Operating income before deduction of amortization|Earnings per share for the last twelve months Intensity Therapeutics|INTS - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months intensitytherapeutics.com|INTS - Net earnings per one share growth for the current year|Earnings growth forecast for next year Intensity Therapeutics
- revenue and sales details:
INTS - Company Total Revenue|Company Projected Revenue Intensity Therapeutics, Inc.|INTS - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio INTS
Summary company analysis:Intensity Tx INTS
Manufactured products of intensitytherapeutics.com

When selecting assets with high fundamental resilience, it is critical to evaluate the ratio of market capitalization to projected revenue during downturns. This forward P/S metric allows for the determination of capital stagnation risk by comparing the valuation of Intensity Therapeutics (INTS) with the expected demand for its AI modules and autonomous robotics systems, reflecting market sentiment through price action.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|STRO (Sutro Biopharma, Inc.) - Forward P/S Multiple|Forward P/S Multiple minktherapeutics.com|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|IMMX: Future Price to Revenue|ALX Oncology Holdings - Forward Price-to-Revenue Multiple|cuebiopharma.com (CUE) - Market Cap to Future Revenue Ratio|PDS Biotechnology Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Sonnet BioTherapeutics SONN|MAIA Biotechnology, Inc. (MAIA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue LIMN|Forward Price-to-Revenue Multiple LVTX|NXTC (NextCure Corporation) - Price to Expected Revenue Ratio|Forward P/S Multiple LPTX|SNSE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Theriva Biologics TOVX|GRTS: Market Cap to Projected Revenue|KA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio NexImmune Corporation NEXI|TSBX: Forward P/S Multiple|VCNX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple HARP